Goldman Sachs assigned a Neutral rating and $20 price target to Edgewise Therapeutics (EWTX) after having previously covered the stock with an Early-Stage Biotech rating. While the firm sees blockbuster potential for the company’s programs across multiple indications including sevasemten in Becker muscular dystrophy, where there is no currently approved FDA therapy, and Duchenne muscular dystrophy, it also sees limited opportunities for the stock to re-rate over the next 12 months given expected clinical and regulatory updates.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics downgraded to Neutral from Buy at Goldman Sachs
- JPMorgan cuts Edgewise target, remains from Analyst Focus List
- Edgewise Therapeutics Advances in Muscular Dystrophy Trials
- Edgewise Therapeutics: Strong Financial Health and Promising Clinical Advances Drive Buy Rating
- Edgewise Therapeutics reports Q2 EPS (34c), consensus (42c)